<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609828</url>
  </required_header>
  <id_info>
    <org_study_id>A4091061</org_study_id>
    <secondary_id>2013-002223-42</secondary_id>
    <secondary_id>CANCER PAIN PH 3 SC STUDY</secondary_id>
    <nct_id>NCT02609828</nct_id>
  </id_info>
  <brief_title>Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy</brief_title>
  <official_title>A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether tanezumab is effective in the treatment of&#xD;
      cancer pain due to bone metastasis in patients already taking background opioid therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter, parallel-group Phase 3&#xD;
      study in cancer subjects requiring treatment with background opioids for pain due to bone&#xD;
      metastasis.&#xD;
&#xD;
      Approximately 144 subjects will be randomized to one of 2 treatment groups in a 1:1 ratio&#xD;
      (approximately 72 subjects per group). Subjects will receive a total of 3 subcutaneous&#xD;
      injections, separated by 8 weeks in addition to background opioids administered throughout&#xD;
      the study.&#xD;
&#xD;
      Treatment groups will include: 1. Placebo SC (matching tanezumab SC) in addition to&#xD;
      background opioid therapy. 2. Tanezumab 20 mg SC in addition to background opioid therapy.&#xD;
&#xD;
      The study consists of three periods: Pre-Treatment (up to 37 days), Double-Blind Treatment&#xD;
      (24 weeks) and Safety Follow-up (24 weeks).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2015</start_date>
  <completion_date type="Actual">June 25, 2021</completion_date>
  <primary_completion_date type="Actual">September 17, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in daily average pain intensity in index bone metastasis cancer pain site</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from Baseline to Week 8 in the daily average pain intensity Numerical Rating Score (NRS) in the index bone metastasis cancer pain site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daily average pain intensity in index bone metastasis cancer pain site</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 1, 2, 4, 6, 12, 16 and 24 in the daily average pain intensity NRS score in the index bone metastasis cancer pain site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daily worst pain intensity in index bone metastasis cancer pain site</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the daily worst pain intensity NRS score in the index bone metastasis cancer pain site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly average pain intensity in non-index cancer pain sites</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the weekly average pain intensity NRS score in non-index cancer pain sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly worst pain intensity in non-index cancer pain sites</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the weekly worst pain intensity NRS score in non-index cancer pain sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daily average pain intensity in non-index visceral cancer pain sites</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the daily average pain intensity NRS score in the non-index visceral cancer pain sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daily worst pain intensity in non-index visceral cancer pain sites</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the daily worst pain intensity NRS score in the non-index visceral cancer pain sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Brief Pain Inventory (BPI) average pain score</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 2, 4, 8, 16 and 24 in the Brief Pain Inventory (BPI) average pain scores obtained at study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BPI worst pain score</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 2, 4, 8, 16 and 24 in the BPI worst pain scores obtained at study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response as defined by a 30%, 50%, 70%, and 90% reduction from Baseline in the daily average and daily worst pain intensity NRS score in the index bone metastasis cancer pain site</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Response as defined by a 30%, 50%, 70%, and 90% reduction from baseline in the daily average and daily worst pain intensity NRS score in the index bone metastasis cancer pain site at Weeks 1, 2, 4, 6, 8, 12, 16 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient's Global Assessment of Cancer Pain</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline in Patient's Global Assessment of Cancer Pain at Weeks 2, 4, 8, 16 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response defined as an improvement of 2 points in Patient's Global Assessment of Cancer Pain</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Response defined as an improvement of 2 points in Patient's Global Assessment of Cancer Pain at Weeks 2, 4, 8, 16 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the BPI Pain Interference with Function composite score and individual pain interference item scores</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 2, 4, 8, 16 and 24 in the BPI Pain Interference with Function Composite Score and individual pain interference item scores obtained at study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol 5 Dimension (EQ-5D-5L) dimensions and overall health utility score</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>EuroQol 5 Dimension (EQ-5D-5L) dimensions and overall health utility score at Baseline and Weeks 8, 16 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily total opioid consumption (in mg of morphine equivalent doses)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Average daily total opioid consumption (in mg of morphine equivalent doses) at Weeks 1, 2, 4, 6, 8, 12, 16 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average number of doses of rescue medication required per week</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Average number of doses of rescue medication required per week at Weeks 1, 2, 4, 6, 8, 12, 16 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly Opioid-Related Symptom Distress Scale</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline in the weekly Opioid-Related Symptom Distress Scale at Weeks 2, 4, 8, 16, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Summary listing of adverse events for each participant; Summary of risk differences between each tanezumab group and placebo for common adverse events and for selected adverse events of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard safety assessments</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Summary listing of safety laboratory testing [chemistry, hematology], sitting vital signs, ECG [12-lead]) for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orthostatic (supine/standing) blood pressure assessment</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Orthostatic (supine/standing) blood pressure assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight and Height measurements, Physical examinations.</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Weight measurements (pounds or kilograms), Height measurements (inches or centimeters), Body Mass Index (kg per meter squared), Physical examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic examination (Neuropathy Impairment Score [NIS]).</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Neurologic examination (Neuropathy Impairment Score [NIS]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survey of Autonomic Symptom scores</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Survey of Autonomic Symptom scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA) assessments</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Anti-drug antibody (ADA) assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint safety adjudication outcomes</measure>
    <time_frame>Up to 48 weeks, or up to 24 weeks following total joint replacement procedure</time_frame>
    <description>Number of subjects with adjudicated events of rapidly progressive osteoarthritis type 2, subchondral insufficiency fractures or spontaneous osteonecrosis of the knee, primary osteonecrosis, or pathological fracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total joint replacements</measure>
    <time_frame>Up to 24 weeks post-procedure</time_frame>
    <description>Total joint replacements</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Bone Metastasis</condition>
  <condition>Cancer Pain</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tanezumab 20 mg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to active treatment subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tanezumab</intervention_name>
    <description>Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>PF-04383119</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Personally signed and dated informed consent document.&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study procedures.&#xD;
&#xD;
          -  Male or female, ≥18 years of age&#xD;
&#xD;
          -  Weight ≥40 kg at Screening&#xD;
&#xD;
          -  Cancer diagnosed as having metastasized to bone or multiple myeloma.&#xD;
&#xD;
          -  Imaging confirmation of bone metastasis at Screening or within 120 days prior to the&#xD;
             Screening visit.&#xD;
&#xD;
          -  Expected to require daily opioid medication throughout the course of the study.&#xD;
&#xD;
          -  Willing to not use prohibited medications (including NSAIDs) throughout the duration&#xD;
             of the study.&#xD;
&#xD;
          -  Average Pain Score ≥5 at Screening for the index bone metastasis cancer pain site.&#xD;
&#xD;
          -  Patient's Global Assessment of Cancer Pain of &quot;fair&quot;, &quot;poor&quot; or &quot;very poor&quot; at&#xD;
             Screening.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0, 1, or 2 at&#xD;
             Screening.&#xD;
&#xD;
          -  Adequate bone marrow, renal and liver function at Screening.&#xD;
&#xD;
          -  International Normalized Ratio (INR) or prothrombin time (PT) &lt;1.5 x ULN at Screening&#xD;
             unless being treated with anticoagulant medication.&#xD;
&#xD;
          -  Females must either be not of childbearing potential or, if of childbearing potential&#xD;
             and at risk for pregnancy, must be willing to use at least one highly effective method&#xD;
             of contraception throughout the study and for 112 days (16 weeks) after the last dose&#xD;
             of assigned subcutaneous study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pain related to an oncologic emergency.&#xD;
&#xD;
          -  Brain metastasis or leptomeningeal metastasis.&#xD;
&#xD;
          -  Presence of hypercalcemia at Screening.&#xD;
&#xD;
          -  Pain primarily classified as not predominantly related to a bone metastasis.&#xD;
&#xD;
          -  Systemic treatment for the primary malignancy or bone metastasis started within 30&#xD;
             days of the Baseline Assessment Period.&#xD;
&#xD;
          -  Chemotherapies associated with peripheral neuropathy (ie, paclitaxel, docetaxel,&#xD;
             oxaliplatin, cisplatin, vincristine, thalidomide or bortezomib) are prohibited during&#xD;
             the study from 30 days prior to the first day of the Baseline Assessment Period to&#xD;
             Week 48.&#xD;
&#xD;
          -  Receipt of radiopharmaceutical treatment or radiotherapy for treatment of bone&#xD;
             metastasis within 30 days of the Baseline Assessment Period.&#xD;
&#xD;
          -  Concurrent adjuvant analgesics unless started at least 30 days prior to the start of&#xD;
             the Baseline Assessment Period and maintained at a stable dose.&#xD;
&#xD;
          -  Diagnosis of osteoarthritis of the knee or hip or findings consistent with&#xD;
             osteoarthritis in the shoulder.&#xD;
&#xD;
          -  History of significant trauma or surgery to a major joint within one year prior to&#xD;
             Screening.&#xD;
&#xD;
          -  History of osteonecrosis or osteoporotic fracture.&#xD;
&#xD;
          -  X-ray evidence at Screening of: 1) rapidly progressive osteoarthritis, 2) atrophic or&#xD;
             hypotrophic osteoarthritis, 3) subchondral insufficiency fracture, 4) spontaneous&#xD;
             osteonecrosis of the knee (SPONK), 5) osteonecrosis, or 6) pathologic fracture.&#xD;
&#xD;
          -  Signs and symptoms of clinically significant cardiac disease.&#xD;
&#xD;
          -  Evidence of orthostatic hypotension at Screening or at Baseline prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Diagnosis of a transient ischemic attack in the 6 months prior to Screening or&#xD;
             diagnosis of stroke with significant residual deficits.&#xD;
&#xD;
          -  History, diagnosis, or signs and symptoms of clinically significant neurological&#xD;
             disease.&#xD;
&#xD;
          -  Total impact score of &gt;7 on the Survey of Autonomic Symptoms (SAS) at Screening.&#xD;
&#xD;
          -  Past history of carpal tunnel syndrome (CTS) with signs or symptoms of CTS in the one&#xD;
             year prior to Screening.&#xD;
&#xD;
          -  History of significant alcohol, analgesic, or narcotic substance abuse within the six&#xD;
             months prior to Screening.&#xD;
&#xD;
          -  Planned surgical procedure during the duration of the study.&#xD;
&#xD;
          -  Considered unfit for surgery or not willing to undergo joint replacement surgery if&#xD;
             required.&#xD;
&#xD;
          -  Known hypersensitivity to opioids or an underlying medical condition contraindicating&#xD;
             opioid use.&#xD;
&#xD;
          -  History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal&#xD;
             antibody or IgG-fusion protein.&#xD;
&#xD;
          -  Previous exposure to exogenous nerve growth factor or to an anti-nerve growth factor&#xD;
             antibody.&#xD;
&#xD;
          -  Presence of drugs of abuse, prescription medications without a valid prescription or&#xD;
             other illegal drugs at Screening.&#xD;
&#xD;
          -  Positive Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) tests at&#xD;
             Screening indicative of current infection.&#xD;
&#xD;
          -  Investigational site staff members and their family members, or Pfizer employees&#xD;
             directly involved in the conduct of the trial.&#xD;
&#xD;
          -  Participation in other studies involving investigational drug(s) within 30 days (or 90&#xD;
             days for investigational biologics) before Baseline Assessment Period and/or during&#xD;
             study participation.&#xD;
&#xD;
          -  Pregnant female subjects; breastfeeding female subjects; female subjects of&#xD;
             childbearing potential who are unwilling or unable to use one (1) highly effective&#xD;
             method of contraception throughout the study and for 112 days after last dose of&#xD;
             investigational product.&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Oncologia de Rosario</name>
      <address>
        <city>Rosario</city>
        <state>Santa FE</state>
        <zip>S2000KZE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>East Bentleigh</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landesklinikum Krems</name>
      <address>
        <city>Krems</city>
        <zip>3500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuhr Medical Center</name>
      <address>
        <city>Senftenberg</city>
        <zip>3541</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associacao Hospital de Caridade de Ijui</name>
      <address>
        <city>Ijui</city>
        <state>RIO Grande DO SUL</state>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INCA - Instituto Nacional do Cancer / Hospital do Cancer HCIII</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20560-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Pio XII-Hospital de Cancer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>SAO Paulo</state>
        <zip>14.784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Ensino e Pesquisa da Fundacao Amaral Carvalho</name>
      <address>
        <city>Jau</city>
        <state>SAO Paulo</state>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao do ABC - Faculdade de Medicina do ABC - CEPHO</name>
      <address>
        <city>Santo Andre</city>
        <state>SAO Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral</name>
      <address>
        <city>Itajai</city>
        <state>SC</state>
        <zip>88.301-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao do ABC-Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital AC Camargo_Fundacao Antonio Prudente</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01509-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clinica do IBCC - Instituto Brasileiro de Controle do Cancer</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>03102-006</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital AC Camargo_Fundacao Antonio Prudente</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01509-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Lind Centro de lnvestigacion del Cancer</name>
      <address>
        <city>Araucania</city>
        <zip>4800827</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University, Department of Medical Oncology</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fifth Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daping Hospital, Research Institute of Surgery Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital/Oncology Department</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital/Respiration internal medicine</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology/Cancer Center</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Department, West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urocentrum Plzen Research Site s.r.o.</name>
      <address>
        <city>Plzen</city>
        <zip>30100</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze, Fakultni poliklinika, Centrum pro lecbu bolesti</name>
      <address>
        <city>Praha 2</city>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veszprem Megyei Tudogyogyintezet Farkasgyepu</name>
      <address>
        <city>Farkasgyepu</city>
        <zip>8582</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Ltd., MISEK Hematology Department-CRU Co.</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Ltd., MISEK-CRU</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josa Andras Hospital, Clinical Research Department</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Help-MR Diagnosztika Kft.</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HaEmek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Toyohashi Medical Center</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <zip>440-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center</name>
      <address>
        <city>Ota</city>
        <state>Gunma</state>
        <zip>373-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishinomiya Municipal Central Hospital</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital of Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saga-Ken Medical Centre Koseikan</name>
      <address>
        <city>Saga</city>
        <zip>840-8571</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Tokyo Medical Center</name>
      <address>
        <city>Tokyo</city>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Pharmacy, National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imaging Facilities, National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Pharmacy, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imaging Facilities, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Powiatowy Zespol Zakladow Opieki Zdrowotnej Oddzial Opieki Paliatywnej</name>
      <address>
        <city>Bedzin</city>
        <zip>42-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Vitamed im. Edyty Jakubow</name>
      <address>
        <city>Bialystok</city>
        <zip>15-215</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poradnia Otropedyczno-Urazowa; Gabient RTG</name>
      <address>
        <city>Bialystok</city>
        <zip>15-437</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pracownia RTG Helimed</name>
      <address>
        <city>Czeladz</city>
        <zip>41-250</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej, Zespol Medyczno-Opiekunczy Alicja Kluczna</name>
      <address>
        <city>Dabrowa Gornicza</city>
        <zip>41-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospicjum im. Ks. Eugeniusza Dutkiewicza SAC w Gdansku</name>
      <address>
        <city>Gdansk</city>
        <zip>80-208</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stowarzyszenie Przyjaciol Chorych Hospicjum w Gliwicach NZOZ Hospicjum Milosierdzia Bozego</name>
      <address>
        <city>Gliwice</city>
        <zip>44-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stowarzyszenie Przyjaciol Chorych Hospicjum w Gliwicach, NZOZ Hospicjum Milosierdzia Bozego</name>
      <address>
        <city>Gliwice</city>
        <zip>44-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalny Szpital Specjalistyczny im. Dr. Wl.Bieganskiego, Oddzial Onkologii Klinicznej</name>
      <address>
        <city>Grudziadz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCANiX Sp.z o.o</name>
      <address>
        <city>Katowice</city>
        <zip>40-057</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ &quot;Vegamed&quot;</name>
      <address>
        <city>Katowice</city>
        <zip>40-060</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helimed Diagnostic Imaging Sp. z o.o., Sp. komandytowa</name>
      <address>
        <city>Katowice</city>
        <zip>40-760</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helimed Diagnostic Imaging Sp. z.o.o., Sp. komandytowa</name>
      <address>
        <city>Katowice</city>
        <zip>40-760</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Diagnostyki Obrazowej EPIONE</name>
      <address>
        <city>Katowice</city>
        <zip>40-872</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Neuromed M. i M. Nastaj Sp. P.</name>
      <address>
        <city>Lublin</city>
        <zip>20-064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK Przemienienia Panskiego UM im. Karola Marcinkowskiego w Poznaniu,</name>
      <address>
        <city>Poznan</city>
        <zip>61-245</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Nowotworow Piersi i Chirurgii Rekonstrukcyjnej w Centrum Onkologii -Instytucie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital LUX MED</name>
      <address>
        <city>Warszawa</city>
        <zip>02-801</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Oncolab SRL</name>
      <address>
        <city>Craiova</city>
        <state>Dolj</state>
        <zip>200385</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Oncocenter Oncologie Clinica S.R.L.</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300166</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic C.F. 2 Bucuresti. Departament Oncologie, Sectia Medicala 2</name>
      <address>
        <city>Bucuresti</city>
        <zip>011464</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Národný onkologický ústav</name>
      <address>
        <city>Bratislava</city>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DEMOMED s.r.o.</name>
      <address>
        <city>Nove Zamky</city>
        <zip>94001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Viliam Cibik, PhD, s.r.o.</name>
      <address>
        <city>Pruske</city>
        <zip>018 52</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna Nemocnica S Poliklinikou Zilina</name>
      <address>
        <city>Zilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche Servicio de Farmacia</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Can Misses</name>
      <address>
        <city>Ibiza</city>
        <state>Islas Baleares</state>
        <zip>07800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Moraleja</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Tooting</city>
        <state>London</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian, Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian, Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091061&amp;StudyName=A%20Phase%203%20Randomized%2C%20Double-blind%2C%20Placebo-controlled%2C%20Multicenter%20Study%20Of%20The%20Analgesic%20Efficacy%20And%20Safety%20Of%20The%20Subcutaneous%20Administration%20Of%20Tanezumab%20%28pf-04383119%29%20In%20Subjects%20With%20Cancer%20Pain%20Predominantly%20Due%20To%20Bone%20Metastasis%20Receiving%20Background%20Opioid%20Therapy</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <disposition_first_submitted>June 3, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>June 3, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 11, 2021</disposition_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic cancer bone pain</keyword>
  <keyword>Multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tanezumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <pending_results>
    <submitted>October 25, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

